Management’s guidance upgrade for FY19
13/01/20 -"Given the strong uptake of Cimzia (33% of sales) and Vimpat (25% of sales) across geographies in Q4 19, we have upgraded our revenue estimates for the forecast years. Combined with robust operational ..."
Pages
51
Language
English
Published on
13/01/20
You may also be interested by these reports :
06/10/25
Over the week ending 3 October, equity markets delivered another strong performance. In Europe, the STOXX 600 rose 2.9%, driven by a massive rebound ...
03/10/25
We have materially upgraded our earnings estimates for UCB, keeping in view the vigorous uptake of the immunology drug Bimzelx, and a strong support ...
29/09/25
Genmab is strategically acquiring Merus to expand its late-stage portfolio with head and neck cancer treatments, addressing anticipated declines in ...
24/09/25
When we last pushed the Spanish blood plasma giant Grifols’ (BUY ; Spain) investment case in May 2024, investor confidence was close to its nadir, as ...